Fimepinostat

Generic Name
Fimepinostat
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C23H24N8O4S
CAS Number
1339928-25-4
Unique Ingredient Identifier
3S9RX35S5X
Background

Fimepinostat (CUDC-907) has been used in trials studying the treatment of lymphoma, solid tumors, breast cancer, multiple myeloma, and NUT midline carcinoma, among others.

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

Fimepinostat, Combination HDAC and Pi3-kinase Inhibitor Tumor-Directed Therapy for Cushing Disease

Phase 2
Not yet recruiting
Conditions
Cushing Disease
Interventions
Drug: Fimepinostat
First Posted Date
2023-08-02
Last Posted Date
2023-08-02
Lead Sponsor
University of California, Los Angeles
Target Recruit Count
20
Registration Number
NCT05971758

Fimepinostat in Treating Brain Tumors in Children and Young Adults

First Posted Date
2019-03-28
Last Posted Date
2024-08-19
Lead Sponsor
Sabine Mueller, MD, PhD
Target Recruit Count
30
Registration Number
NCT03893487
Locations
🇺🇸

Nationwide Children's, Columbus, Ohio, United States

🇺🇸

Children's National Medical Center, Washington, District of Columbia, United States

🇨🇭

The University Children's Hospital in Zurich, Zürich, Zurich, Switzerland

and more 16 locations

Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma

First Posted Date
2012-12-06
Last Posted Date
2021-05-06
Lead Sponsor
Curis, Inc.
Target Recruit Count
106
Registration Number
NCT01742988
Locations
🇺🇸

Winship Cancer Institute, Emory University, Atlanta, Georgia, United States

🇺🇸

Florida Cancer Specialists, Sarasota, Florida, United States

🇺🇸

University of Chicago Medicine, Chicago, Illinois, United States

and more 8 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy